The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).
Wouter Willem Mellema
No relevant relationships to disclose
Lucie Masen-Poos
No relevant relationships to disclose
Lizza Hendriks
No relevant relationships to disclose
Anthonie Van Der Wekken
No relevant relationships to disclose
Joachim Aerts
No relevant relationships to disclose
Judith Herder
No relevant relationships to disclose
Jos Stigt
No relevant relationships to disclose
Ben Van Den Borne
No relevant relationships to disclose
Michel M van den Heuvel
No relevant relationships to disclose
Ellen Pouw
No relevant relationships to disclose
Anne-Marie C. Dingemans
No relevant relationships to disclose
Egbert F. Smit
No relevant relationships to disclose